Search

Background: The first signal of a new infection is often severe cases presenting at hospital. Enhanced surveillance of these cases is critical to learning more about disease epidemiology and patient outcomes, but nationallevel surveillance can lack power to draw conclusions. In response to the emergence of SARS-CoV-2, the Influenza-Monitoring Vaccine Effectiveness (I-MOVE) network, founded in 2007, expanded to establish the I-MOVE-COVID-19 Consortium in February 2020. The Consortium’s surveillance objectives included using pooled data to describe clinical and epidemiological characteristics of hospitalised COVID-19 patients across Europe, in order to contribute to the knowledge base, guide patient management, and inform public health response. Methods: Eleven study sites participated in the surveillance, including 23 hospitals across six EU Member States and Albania, and hospitals nationally in England and Scotland. A standardised protocol and dataset for collection was agreed by April 2020. In England and Scotland, data were generated by linkage of routine datasets; other sites used bespoke paper or electronic questionnaires. Data were submitted, pooled and analysed quarterly. Results: Data were received regarding 84,297 COVID-19 patients hospitalised between 1 February 2020 and 31 January 2021. Three surveillance bulletins were published between September 2020 and March 2021, providing key insights into severe COVID-19 at European level. However, the unexpected, overwhelming workload at participating sites, and difficulties securing data protection and ethics permissions, delayed data submissions and presented challenges for timely analysis. Conclusions: Building on an existing network facilitated a novel European multicentre hospital surveillance system to be implemented during a pandemic; however, timeliness was nonetheless problematic. In future, processes could be streamlined e.g. by developing pre-approved template protocols with information governance and ethical approvals in place during the inter- pandemic period. The I-MOVE-COVID-19 network has received funding from the European Commission (from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 101003673). N/A

Background: The I-MOVE-COVID-19 Consortium was established to conduct surveillance of hospitalised COVID-19 cases in nine European countries, aiming to describe the clinical and epidemiological characteristics of severe COVID-19 in order to inform public health response. Methods: Data are pooled from 11 participating sites; two (England and Scotland) submitting national data, with the remainder being from a selection of hospitals. Descriptive analysis is performed on the pooled dataset overall and comparing data on patients admitted from week 5 to 28 of 2020 (“first wave”) vs those admitted later (“second wave”). Results: Data on 84,297 hospitalised patients were submitted for 01 February 2020 - 31 January 2021. Fifty-six percent of cases (46,907/84,193) were male and median age was 69 years. Where information was available, 44% (25,344 /57,769) patients were recorded as having at least one chronic condition. Ninety-five percent (7,868/8,270 and 90% (5,606/6,231) were reported with respiratory and febrile presentations respectively. Twenty-four percent (18,795/78,955) were admitted to intensive care units (ICU) and 26% (19,805/76,764) died in hospital (all sites); 12% (3,305/28,262) and 20% (5,454/27,066) respectively for all sites except England (where ICU reporting is mandated, biasing the dataset towards more severe outcomes as this site represents >50% of all cases). As a percentage of all hospital admissions, both ICU admissions and deaths decreased significantly between the first and second waves in both sexes and across all age- groups, apart from the over 75s. Conclusions: Results from this multicentre European surveillance system suggest that about one in 10 hospitalised COVID-19 patients are admitted to ICU and one in five have fatal outcomes. Fatality and ICU admission were lower in the second wave compared with the first. The I-MOVE-COVID-19 network has received funding from the European Commission (from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 101003673). N/A

Generic protocol for measuring COVID-19 vaccine effectiveness at primary care level in Europe - part of the I-MOVE-COVID-19 project, This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101003673.

This document presents the core I-MOVE-COVID-19 European protocol for the hospital-based study of potential risk and protective factors for severe COVID-19 in hospitalised COVID-19 patients, outlining the agreed methods for collecting COVID-19 and SARS-CoV-2 in each of the individual studies, and including a plan for the pooled analysis., This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101003673

This document presents the core European protocol for the hospital-based surveillance component of I-MOVE-COVID-19 for 2020, outlining the agreed methods for collecting COVID-19 and SARS-CoV2 data during this pandemic., This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101003673

This document presents the core I-MOVE-COVID-19 European protocol for the 2020 hospital-based study of vaccine effectiveness against COVID-19 in hospitalised SARI patients of all ages, outlining the agreed methods for collecting data on COVID-19 and SARS-CoV-2 in each of the individual studies, and including a plan for the pooled analysis., This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101003673

This document presents the core I-MOVE-COVID-19 European protocol for measuring risk and protective factors for COVID-19 at primary care level. The COVID-19 vaccine effectiveness is separate to this., This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101003673 .

This surveillance report summarises the information from the I-MOVE-COVID-19 hospital surveillance networks to monitor the COVID-19 pandemic in nine European countries., This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101003673.

This surveillance report summarises the information from the I-MOVE-COVID-19 primary care surveillance networks to monitor the COVID-19 pandemic in seven European countries. The I-MOVE-COVID-19 surveillance in primary care aims to reinforce and complement the COVID-19 epidemiological data in the EU/EEA and the UK, compiled and reported by ECDC., This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101003673

This surveillance report summarises the information from the I-MOVE-COVID-19 hospital surveillance networks to monitor the COVID-19 pandemic in nine European countries., This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101003673

A generic protocol for COVID-19 surveillance at primary care level - from the I-MOVE-COVID-19 project., This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101003673